190,205 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 190,205 shares of the biotechnology company’s stock, valued at approximately $3,802,000. Thrivent Financial for Lutherans owned about 0.08% of ADMA Biologics at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. D. E. Shaw & Co. Inc. grew its holdings in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Driehaus Capital Management LLC increased its stake in ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after acquiring an additional 447,743 shares during the period. Renaissance Technologies LLC raised its position in ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after purchasing an additional 575,100 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in shares of ADMA Biologics by 15.5% in the 2nd quarter. Federated Hermes Inc. now owns 1,969,811 shares of the biotechnology company’s stock worth $22,022,000 after buying an additional 263,677 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. The trade was a 22.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is owned by insiders.

ADMA Biologics Stock Performance

ADMA stock opened at $21.18 on Monday. The company has a 50 day moving average price of $18.86 and a 200 day moving average price of $14.89. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a market capitalization of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the previous year, the company posted $0.01 earnings per share. Analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the topic of a number of recent analyst reports. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.